Journal News

Influenza gets help from gum disease bacteria

Emily Ulrich
May 15, 2025

Scientists know that bacteria in the respiratory tract, such as specific Staphylococcus aureus strains, can boost influenza infectivity by supplying a protease that cleaves the viral spike protein hemagglutinin, a step that facilitates viral host entry. The bacterium Porphyromonas gingivalis causes periodontal disease and has been associated with severe cases of influenza, but scientists have not determined whether this connection involves hemagglutinin cleavage by a specific enzyme. In a recent article from the Journal of Biological Chemistry, Noriaki Kamio and a team at Nihon University in Japan investigated the link between P. gingivalis and influenza infectivity.

The authors used immunofluorescence microscopy and a canine kidney cell line to determine that an element in the supernatant of P. gingivalis culture enhanced cell-to-cell spread of influenza, similar to cells treated with trypsin protease. The researchers hypothesized that the supernatant contains a protease that can cleave viral hemagglutinin. They suspected that the gingipain cysteine proteases Rgp and Kgp produced by P. gingivalis could perform this function.

They tested the involvement of each protease by adding individual inhibitors of Rgp and Kgp to the supernatant and found that only the Rgp inhibitor blocked hemagglutinin cleavage. In addition, the authors showed that supernatant from a P. gingivalis strain lacking Rgp could not cleave hemagglutinin. They also performed a plaque assay to measure viral titers and found that the viral concentration was lower when cells were incubated with the bacterial strain missing Rgp. Therefore, they concluded that Rgp likely cleaves hemagglutinin and enhances viral replication.

The authors suggested that future studies using human respiratory cells and animal models will help unravel details of how P. gingivalis strengthens influenza infectivity. These results may help scientists pinpoint proteins in other bacteria that may promote respiratory viral spread.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Emily Ulrich

Emily Ulrich is ASBMB’s former science editor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Building a better model for drug delivery across the blood–brain barrier
Journal News

Building a better model for drug delivery across the blood–brain barrier

May 19, 2026

Industry and academic scientists collaborated to develop a rat with humanized iron-transport receptors, enabling research into iron homeostasis and drugs that cross the brain’s barrier.

Fat synthesis enzyme crucial for milk fat and newborn growth
Journal News

Fat synthesis enzyme crucial for milk fat and newborn growth

May 14, 2026

Researchers found that a deficiency of the fatty acid synthesis enzyme stearoyl-CoA desaturase-1 reduced mammary gland function during lactation and caused low birth weight in newborns that were fed milk from enzyme-deficient glands.

Flipping lipids and slime molds
Interview

Flipping lipids and slime molds

May 12, 2026

A dull first job nearly pushed JBC associate editor Todd Graham out of science. Then a slime mold project changed his path. Now, he studies membrane biology and reflects on discovery, persistence and mentoring through uncertainty.

How smelling death alters worm behavior
News

How smelling death alters worm behavior

May 7, 2026

Researchers have found that the roundworm C. elegans can smell death, and it changes how the worms behave, reproduce and age.

A chance encounter with the lab
Profile

A chance encounter with the lab

May 5, 2026

Payton Stevens never planned to become a pancreatic cancer researcher. A temporary job set him on a path from rural Kentucky to leading research on Wnt signaling and metastasis, where he now pairs discovery with mentorship and science advocacy.

Light-activated small molecule could transform eye infection treatment
News

Light-activated small molecule could transform eye infection treatment

April 21, 2026

Contact lenses raise the risk of infectious keratitis, a leading cause of blindness worldwide. A biotech company is commercializing a light-activated therapy using a ROS-generating molecule to rapidly kill microbes in the cornea to preserve vision.